research use only

Atropine sulfate monohydrate ADC Cytotoxin inhibitor

Name: Atropine sulfate monohydrate
Brand: Selleck Chemicals
SKU: S2130
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S2130

Atropine sulfate monohydrate is a competitive antagonist for the muscarinic acetylcholine receptor, used to decrease the production of saliva and secretions of the airway prior to surgery.

Chemical Structure

Molecular Weight: 694.83

Jump to

Quality Control

Batch: Purity: 99.78%

99.78

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE)
Other ADC Cytotoxin Inhibitors	Triptolide SN-38 Luteolin (+)-Bicuculline Rutin Artemisinin Pinocembrin Harmine hydrochloride Luteoloside BHQ

Solubility

In vitro
Batch:

DMSO : 139 mg/mL (200.04 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 139 mg/mL

Ethanol : 139 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	694.83	Formula	2(C₁₇H₂₃NO₃).H₂O.H₂SO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	5908-99-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.O.OS(=O)(=O)O

Mechanism of Action

Targets/IC₅₀/Ki	mAChR 2.5 nM
In vitro	Atropine increases the release of the neurotransmitter dopamine into the superfusate in vitro at 100-500 mM and into the vitreous in vivo at 250 mg. Atropine induces spreading depression (SD) in the in vitro preparation. Atropine reduces the ERG b- and d-wave, leads to damped oscillations of RPE potentials, and reverses the ERG c-wave. Atropine suppresses myopia only at doses at which severe nonspecific side effects are observed in the retina.
In vivo	Atropine (1.0 mg/kg, i.p.), but not methylatropine (1.0 mg/kg, i.p.), prevents the enhancement of retention induced by both doses of the anticholinesterase when given immediately after training in mice. Atropine administration effectively prevents bradycardia and second-degree heart block but induces pulsus alternans and hypertension in dogs. Atropine has no effect on handling-induced acetylcholine output in the presence of 10 nM neostigmine, but causes greater and longer increases in the presence of 100 nM and 1000 nM neostigmine in rats. Atropine not only blocks the rapid eye movement (REM) sleep increases induced by CGS but it also tends to decrease REM sleep compared to atropine preceding saline in rats. Atropine decreases the time to exhaustion by 67% in intact rats and by 96.2% in adrenodemedullated (ADM) and also reduces the exercise-induced pituitary prolactin (PRL) release in both intact (50%) and ADM rats (90%).
References	[1] https://pubmed.ncbi.nlm.nih.gov/10824671/ [2] https://pubmed.ncbi.nlm.nih.gov/12821180/ [3] https://pubmed.ncbi.nlm.nih.gov/11149715/ [4] https://pubmed.ncbi.nlm.nih.gov/9483538/ [5] https://pubmed.ncbi.nlm.nih.gov/12573729/ [6] https://pubmed.ncbi.nlm.nih.gov/11716582/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06291363	Not yet recruiting	Opioid Use Unspecified\|Anesthesia\|Nociceptive Pain	Ciusss de L''Est de l''Île de Montréal	April 4 2024	Phase 4
NCT06263946	Recruiting	Myopia	Essilor International	March 22 2024	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):